Sign in

NCT03209414Recruiting

Frailty Syndrome in Daily Practice of Interventional Cardiology Ward

Source: ClinicalTrials.gov · Last updated 12 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The impact of frailty on immediate and long term outcomes of invasive treatment of coronary artery disease is not fully characterized. The assessment of frailty may help physicians in the selection of best treatment option and in the timing and modality of the follow-up. The FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is designed with the aim to validate the use of the Fried frailty scale and instrumental activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome (ACS). The FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure, hospital readmission for any cause, and a composite of the above mentioned. Ancillary analyses will be focused on different clinical presentations, different tools to assess frailty and risk stratification. The FRAPICA program will fill critical gaps in the understanding of the relation between frailty, cardiovascular disease, interventional procedures and outcome. It will enable more personalized risk assessment and identification of new targets for interventions.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
24 Jun 2017
Start date
17 May 2017
Primary completion date
31 Dec 2024
Lead sponsor
Medical University of Silesia
NCT number
NCT03209414

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 17 May 2017 to the primary completion date, 31 Dec 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • lack of consent

Who the study is looking for

  • aged ≥ 65
  • symptomatic coronary artery disease A) stable B) unstable C) NSTEMI D) STEMI
  • written, informed consent

Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
II Dept. of Cardiology in Zabrze Medical University of Silesia
Coordinator of this site? Confirm its status
ZabrzePolandRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.